Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies
Standard cancer therapies sometimes fail to deliver chemotherapeutic drugs to tumor cells
in a safe and effective manner. Nanotechnology takes the lead in providing new therapeutic …
in a safe and effective manner. Nanotechnology takes the lead in providing new therapeutic …
The emerging role of complement proteins as a target for therapy of IgA nephropathy
DV Rizk, N Maillard, BA Julian, B Knoppova… - Frontiers in …, 2019 - frontiersin.org
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide
and a common cause of end-stage renal disease. Evaluation of a kidney biopsy is …
and a common cause of end-stage renal disease. Evaluation of a kidney biopsy is …
African swine fever vaccinology: the biological challenges from immunological perspectives
JJ Zhu - Viruses, 2022 - mdpi.com
African swine fever virus (ASFV), a nucleocytoplasmic large DNA virus (NCLDV), causes
African swine fever (ASF), an acute hemorrhagic disease with mortality rates up to 100% in …
African swine fever (ASF), an acute hemorrhagic disease with mortality rates up to 100% in …
Multivalent ligand binding to cell membrane antigens: defining the interplay of affinity, valency, and expression density
CM Csizmar, JR Petersburg, TJ Perry… - Journal of the …, 2018 - ACS Publications
Nature uses multivalency to govern many biological processes. The development of
macromolecular and cellular therapies has largely been dependent on engineering similar …
macromolecular and cellular therapies has largely been dependent on engineering similar …
Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics
NM Piche-Nicholas, LB Avery, AC King, M Kavosi… - MAbs, 2018 - Taylor & Francis
ABSTRACT A large body of data exists demonstrating that neonatal Fc receptor (FcRn)
binding of an IgG via its Fc CH2-CH3 interface trends with the pharmacokinetics (PK) of IgG …
binding of an IgG via its Fc CH2-CH3 interface trends with the pharmacokinetics (PK) of IgG …
Clonal redemption and clonal anergy as mechanisms to balance B cell tolerance and immunity
The adaptive immune system is tasked with producing antibodies that recognize a wide
scope of potential pathogens, including those never before encountered, and concurrently …
scope of potential pathogens, including those never before encountered, and concurrently …
Kinetics of Blood–Brain Barrier Transport of Monoclonal Antibodies Targeting the Insulin Receptor and the Transferrin Receptor
WM Pardridge - Pharmaceuticals, 2021 - mdpi.com
Biologic drugs are large molecule pharmaceuticals that do not cross the blood–brain barrier
(BBB), which is formed by the brain capillary endothelium. Biologics can be re-engineered …
(BBB), which is formed by the brain capillary endothelium. Biologics can be re-engineered …
Mathematical models of blood-brain barrier transport of monoclonal antibodies targeting the transferrin receptor and the insulin receptor
WM Pardridge, T Chou - Pharmaceuticals, 2021 - mdpi.com
We develop and analyze mathematical models for receptor-mediated transcytosis of
monoclonal antibodies (MAb) targeting the transferrin receptor (TfR) or the insulin receptor …
monoclonal antibodies (MAb) targeting the transferrin receptor (TfR) or the insulin receptor …
An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer's disease
Although the amyloid β-protein (Aβ) is believed to play an initiating role in Alzheimer's
disease (AD), the molecular characteristics of the key pathogenic Aβ forms are not well …
disease (AD), the molecular characteristics of the key pathogenic Aβ forms are not well …
[HTML][HTML] A new silicon phthalocyanine dye induces pyroptosis in prostate cancer cells during photoimmunotherapy
I Wolf, J Storz, S Schultze-Seemann, PR Esser… - Bioactive Materials, 2024 - Elsevier
Photoimmunotherapy (PIT) combines the specificity of antibodies with the cytotoxicity of light
activatable photosensitizers (PS) and is a promising new cancer therapy. We designed and …
activatable photosensitizers (PS) and is a promising new cancer therapy. We designed and …